

Ellova®

MYO-INOSITOL & FOLIC ACID


PCOS & INFERTILITY, THE KEY FIGURES



- **Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder** affecting women of reproductive age. Nearly all endocrine organs are affected, including the ovaries.
- Although the condition is generally **considered to be underdiagnosed**, **PCOS is believed to affect up to 10% of women** of reproductive age.

▶ This condition impacts women's hormonal balance, leading to infertility. **74%** of PCOS women are infertile.

INSULIN RESISTANCE, THE BREEDING GROUND OF PCOS PATHOGENESIS



WOMEN'S EXPECTATIONS

Trying to conceive when affected by PCOS can become very problematic due to the multiple endocrine disorders linked to this condition. Women are seeking for an **effective solution which can help them get pregnant safely and rapidly.**

ELLOVA®, THE NATURAL SOLUTION TO ENHANCE FERTILITY

NATURAL

Ellova® contains myo-inositol, a natural bioactive traditionally used in Ayurvedic medicine to treat diabetes. Myo-inositol is an essential component of the key messengers involved in the insulin transduction pathway.

COMBINED WITH FOLIC ACID TO FIT PREGNANT WOMEN'S NEEDS

Folic acid supplementation is recommended to pregnant women to **prevent fetal neural tube defects.**

CLINICALLY PROVEN TO ENHANCE PREGNANCY RATES

- **Ellova® restores normal ovarian function** by increasing insulin sensitivity.
- **Ellova® significantly increases the chances of getting pregnant.**
- **Ellova® improves quality of *In Vitro* Fertilization (IVF) cycles** by **increasing the number of top-quality oocytes.**

INNOVATIVE FORM


Easy-to-take orodispersible powder.

Mode of action | See next page
Clinical studies | next page




ELLOVA®, A COMPREHENSIVE MODE OF ACTION

The normal insulin transduction pathway



In PCOS women...




ELLOVA®, A CLINICALLY PROVEN SOLUTION

The beneficial effect of **Ellova®** on infertility in PCOS women has been widely proven.

RESTORATION OF THE OVULATORY FUNCTION

- Double-blind study
- N = 3.602 PCOS women

- Treatment protocol: Myo-inositol 4 g + Folic acid 400 µg
- Duration: 2-3 months




70% OF INFERTILE PCOS WOMEN HAD RETRIEVED A NORMAL OVULATORY FUNCTION WITHIN 2 TO 3 MONTHS OF SUPPLEMENTATION.

IMPROVEMENT OF IVF OUTCOMES

- Double-blind, randomized study
- N= 50 overweight PCOS women undergoing IVF
- Duration: 12 weeks

- Treatment protocol:
Treated group (N=25): Myo-inositol 2 g + Folic acid 400 µg
Control group (N=25): Folic acid 400 µg



BY INCREASING THE NUMBER OF TOP-QUALITY OOCYTES IN PCOS WOMEN, ELLOVA® INDUCED A CLINICAL PREGNANCY IN 40% OF TREATED WOMEN VS 16% IN THE PLACEBO GROUP.

TECHNICAL INFORMATION

- **Actives:** Myo-inositol & Folic acid
- **Presentation:** 5, 30 or 60 sticks in a box

- **Regulatory:** Food supplement
- **Posology:** 1 stick twice daily for at least 3 months

**CLINICALLY PROVEN - NATURAL
NON-INVASIVE TREATMENT - WELL-TOLERATED**



All product related information (including but not limited to therapeutic indications), trademarks, brand names and trade-dress provided herein are used by STRAGEN mainly for B2B purposes, and are the sole property of STRAGEN or under exclusive license. Any use of trademarks or brand names or trade-dress stated herein requires a prior written agreement from STRAGEN.

stragen

STRAGEN PHARMA SA
Chemin du Pré-Fleuri 3 1228 Plan-les-Quates/Geneva Switzerland
tel +41 22 799 19 19 fax +41 22 799 19 99 info@stragen.ch www.stragen.ch